Research on Tumor Drug Resistance Mediated by Epithelial-mesenchymal Transition
DOI:
https://doi.org/10.61173/g7ea4081Keywords:
- Epithelial-mesenchymal transition, tumor drug resistance, treatmentAbstract
Epithelial-mesenchymal transition (EMT) is a key biological process driving tumor invasion and metastasis, and its activation is widely regarded as one of the core mechanisms leading to tumor resistance to multiple therapeutic approaches. Current research indicates that EMT mediates drug resistance through multiple pathways, such as conferring stem cell-like properties to cancer cells, miRNA delivery via exosomes, and promoting drug efflux. The underlying mechanisms of related signaling pathways and key transcription factors are being intensively investigated. However, effectively translating the basic research findings targeting EMT to overcome drug resistance into clinical applications still faces significant challenges. This article systematically reviews the core molecular mechanisms by which EMT mediates tumor drug resistance, with a focus on how EMT confers drug-resistant phenotypes to cancer cells by regulating tumor stem cell characteristics and drug pharmacokinetics. It also reviews experimental strategies targeting key EMT molecules to reverse drug resistance and their preclinical/clinical research evidence. This review provides a theoretical framework for a deeper understanding of the role of EMT in tumor drug resistance and lays the foundation for developing novel combination treatment regimens based on EMT intervention. Future research urgently needs to explore more selective EMT-targeting strategies, identify reliable predictive biomarkers, and optimize their synergistic effects with traditional radiotherapy, chemotherapy, and immunotherapy to ultimately improve the prognosis of patients with refractory tumors.
References
[1] Meacham C. E. and Morrison S. J., “Tumour heterogeneity and cancer cell plasticity,” Nature, vol. 501, no. 7467, pp. 328– 337, 2013.
[2] Shibue T. and Weinberg R. A., “EMT, CSCs, and drug resistance: the mechanistic link and clinical implications,” Nat. Rev. Clin. Oncol., vol. 14, no. 10, pp. 611–629, 2017.
[3] Nieto M. A., Huang R. Y., Jackson R. A., and Thiery J. P., “EMT: 2016,” Cell, vol. 166, no. 1, pp. 21–45, 2016.
[4] Lamouille S., Xu J., and Derynck R., “Molecular mechanisms of epithelial-mesenchymal transition,” Nat. Rev. Mol. Cell Biol., vol. 15, no. 3, pp. 178–196, 2014.
[5] Zheng X., Carstens J., Kim J. et al., “Epithelial-tomesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer,” Nature, vol. 527, pp. 525–530, 2015.
[6] Mallini P., Lennard T., Kirby J., and Meeson A., “Epithelialto-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance,” Cancer Treat. Rev., vol. 40, no. 3, pp. 341–348, 2014.
[7] Zhang Y. E. and Stuelten C. H., “Alternative Splicing in EMT and TGF-β Signaling During Cancer Progression,” Semin. Cancer Biol., vol. 101, pp. 1–11, 2024.
[8] Nachiyappan A., Gupta N., and Taneja R., “EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms,” FEBS J., vol. 289, no. 5, pp. 1329–1351, 2022.
[9] Du B. and Shim J. S., “Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer,” Molecules, vol. 21, p. 965, 2016.
[10] Xu J., Lamouille S., and Derynck R., “TGF-β-induced epithelial to mesenchymal transition,” Cell Res., vol. 19, no. 2, pp. 156–172, 2009.
[11] Zavadil J. et al., “Genetic programs of epithelial cell plasticity directed by transforming growth factor-β,” Oncogene, vol. 23, no. 58, pp. 9395–9404, 2004.
[12] Timmerman L. A. et al., “Notch promotes epithelialmesenchymal transition during cardiac development and oncogenic transformation,” Cancer Cell, vol. 6, no. 5, pp. 451– 463, 2004.
[13] Dennler S. et al., “Induction of sonic hedgehog mediators by transforming growth factor-β: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo,” EMBO J., vol. 26, no. 14, pp. 3346–3356, 2007.
[14] Santos J. C. et al., “Exosome-mediated breast cancer chemoresistance via miR-155 transfer,” Sci. Rep., vol. 8, p. 829, 2018.
[15] Xu H. et al., “Exosomal miR-222-3p contributes to sorafenib resistance in hepatocellular carcinoma by activating PI3K/Akt pathway via suppressing PTEN,” Hepatology, vol. 72, no. 6, pp. 1901–1916, 2020.
[16] Scheel C. et al., “Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast,” Cell Stem Cell, vol. 9, no. 5, pp. 508–522, 2011.
[17] Fischer K. R. et al., “Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance,” EMBO Rep., vol. 16, no. 12, pp. 1649–1663, 2015.
[18] Singh S. et al., “Transforming growth factor-β1 induces EMT and cancer stemness in breast cancer cells via upregulation of ABCG2,” Cell Death Dis., vol. 11, no. 7, p. 515, 2020.
[19] Chang C. J. et al., “EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling,” Nat. Commun., vol. 9, p. 968, 2018.
[20] Wei F. et al., “Exosomes derived from gemcitabineresistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p,” J. Exp. Clin. Cancer Res., vol. 38, no. 1, p. 1, 2019.
[21] Kamerkar S. et al., “Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer,” Nature, vol. 546, no. 7659, pp. 498–503, 2017.
[22] Yin Y. et al., “Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth,” Mol. Cancer, vol. 19, no. 1, p. 1, 2020.
[23] Pastushenko I. et al., “Identification of the tumour transition states occurring during EMT,” Nature, vol. 556, no. 7702, pp. 463–468, 2018.
[24] Mani S. A. et al., “The epithelial-mesenchymal transition generates cells with properties of stem cells,” Cell, vol. 133, no. 4, pp. 704–715, 2008.
[25] Phi L. T. H. et al., “Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment,” Int. J. Mol. Sci., vol. 19, no. 5, p. 1366, 2018.
[26] Mallini P., Lennard T., Kirby J., and Meeson A., “Epithelialto-mesenchymal transition: What is the impact on breast cancer stem cells and drug resistance,” Cancer Treat. Rev., vol. 40, no. 3, pp. 341–348, 2014.
[27] Gupta P. B. et al., “Identification of selective inhibitors of cancer stem cells by high-throughput screening,” Cell, vol. 138, no. 4, pp. 645–659, 2009.
[28] Gupta P. B. et al., “Identification of selective inhibitors of cancer stem cells by high-throughput screening,” Cell, vol. 138, no. 4, pp. 645–659, 2009.
[29] Mateen S. et al., “Epigenetic reprogramming of cancer stem cells by dietary compounds for cancer therapy,” Cell Death Dis., vol. 11, no. 9, p. 1, 2020.
[30] Batlle E. and Clevers H., “Cancer stem cells revisited,” Nat. Rev. Drug Discov., vol. 19, no. 7, pp. 488–509, 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
